NCT05433363 · UNKNOWN
Renji Alzheimer's Disease Neuroimaging Cohort Study
This is an observational imaging study, not a treatment trial. Nobody is given a drug. Researchers use PET-MRI brain scans to look at amyloid, tau, brain sugar use, and small blood vessel damage. They want to see how these relate to early memory decline over time. No phase applies, because nothing is being tested as a therapy.
You may qualify if
- 1) Age: 50-75 years old; 2) complaints of memory decline; 3) Education≥ 6 years; 4) Be able to cooperate with the whole neuropsychological examinations; 5) No PET-MRI or brain MRI contraindications; 6) Sign informed consent.
- normal control: 1) Age: 50-75 years old; 2) No complaints of memory decline; 3) Mini-Mental State Examination (MMSE) ≥ 26 points; 4) Education years ≥ 6 years; 5) Be able to cooperate with a full set of neuropsychological examinations; 6) No PET-MRI or brain MRI contraindications; 7) Sign informed consent.
You're excluded if
- 1) Serious mental illness; 2) Severe depression: Hamilton Depression Scale (HAMD-17) scores ≥ 24; 3) Serious heart, liver, kidney and other important organ diseases; 4) PET-MRI or brain MRI contraindications
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2022-06-27